Welcome to our dedicated page for Contextlogic news (Ticker: LOGC), a resource for investors and traders seeking the latest updates and insights on Contextlogic stock.
ContextLogic Holdings Inc. reports developments as a publicly traded business ownership platform focused on acquiring and building a portfolio of niche, competitively advantaged, long-duration businesses. News about ContextLogic centers on the completed acquisition of US Salt, operating and financial results, acquisition strategy, cash and investment resources, and the company’s evolution into a portfolio ownership model.
Company updates also cover governance and capital-structure matters, including board appointments, audit committee membership, shareholder voting, Delaware reorganization actions, strategic investment arrangements, and securities registration matters. The recurring themes are portfolio ownership, acquisition execution, operating efficiency, and public-company governance.
LogicBio Therapeutics (Nasdaq:LOGC) reported its Q1 2020 financial results, highlighting a net loss of $9.5 million, or $0.41 per share, compared to $7.7 million, or $0.34 per share in Q1 2019. R&D expenses rose to $7.2 million, attributed to increased costs for LB-001 and personnel expansion. The firm is advancing LB-001 for methylmalonic acidemia and is in discussions with the FDA for its IND submission. With $43.2 million in cash, LogicBio expects to fund operations through Q2 2021, despite ongoing challenges posed by the COVID-19 pandemic.